BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 9002767)

  • 21. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.
    Filosso PL; Ruffini E; Oliaro A; Papalia E; Donati G; Rena O
    Eur J Cardiothorac Surg; 2002 May; 21(5):913-7. PubMed ID: 12062286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Somatostatin receptor-based imaging and therapy of digestive endocrine tumors].
    Illouz F; Sadoul JL; Rohmer V
    Ann Endocrinol (Paris); 2010 Sep; 71 Suppl 1():S3-12. PubMed ID: 21237328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there a therapeutic role for octreotide in patients with ectopic Cushing's syndrome?
    Uwaifo GI; Koch CA; Hirshberg B; Chen CC; Hartzband P; Nieman LK; Pacak K
    J Endocrinol Invest; 2003 Aug; 26(8):710-7. PubMed ID: 14669823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The role of somatostatin analogues in the treatment of hypophyseal adenomas].
    Losa M; Mortini P; Giovanelli M
    Minerva Endocrinol; 2003 Mar; 28(1):39-51. PubMed ID: 12621362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatostatin receptor scintigraphy in gastrinomas.
    Jensen RT; Gibril F
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S179-85. PubMed ID: 10604126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy.
    Lebtahi R; Cadiot G; Delahaye N; Genin R; Daou D; Peker MC; Chosidow D; Faraggi M; Mignon M; Le Guludec D
    J Nucl Med; 1999 Oct; 40(10):1602-8. PubMed ID: 10520698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MEN 1 and 2: the role of diagnostic imaging.
    Gollini P; Cataldi A; Fava C
    Radiol Med; 2004; 107(1-2):78-87. PubMed ID: 15031699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pituitary adenomas: the role of 111In-DTPA-octreotide SPET in the detection of minimal post-surgical residues.
    Lauriero F; Pierangeli E; Rubini G; Resta M; D'Addabbo A
    Nucl Med Commun; 1998 Dec; 19(12):1127-34. PubMed ID: 9885802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.
    Stokkel MP; Reigman HI; Verkooijen RB; Smit JW
    J Cancer Res Clin Oncol; 2003 May; 129(5):287-94. PubMed ID: 12750997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The radioguided 111In-pentetreotide surgery in the management of ACTH-secreting bronchial carcinoid.
    Porziella V; Cesario A; Lococo F; Cafarotti S; Margaritora S; D'Errico G; Granone P
    Eur Rev Med Pharmacol Sci; 2011 Jun; 15(6):587-91. PubMed ID: 21796863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
    Usmani S; Khan HA; Abdulla M; Ahmed N; abu Huda F; Marafi F; al Kandari F; al Mohannadi S; al Nafisi N
    Med Princ Pract; 2011; 20(4):356-61. PubMed ID: 21576997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ECTOPIC CUSHING SYNDROME: A 10-YEAR EXPERIENCE FROM A TERTIARY CARE CENTER IN SOUTHERN INDIA.
    Sathyakumar S; Paul TV; Asha HS; Gnanamuthu BR; Paul MJ; Abraham DT; Rajaratnam S; Thomas N
    Endocr Pract; 2017 Aug; 23(8):907-914. PubMed ID: 28614007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Octreoscan in patients with bronchial carcinoid tumours.
    Granberg D; Sundin A; Janson ET; Oberg K; Skogseid B; Westlin JE
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):793-9. PubMed ID: 14974924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Isotopic scan with somatostatin receptors in a case of recurrent carcinoid tumor. Relevance of tomographic detection].
    Bernà Roqueta L; Martín Marimón JC; Martín Martínez J
    Rev Esp Med Nucl; 2002 Apr; 21(2):123-4. PubMed ID: 11879622
    [No Abstract]   [Full Text] [Related]  

  • 36. Recurrent ectopic adrenocorticotropic hormone producing thymic carcinoid detected with octreotide imaging.
    Silva F; Vázquez-Sellés J; Aguilö F; Vázquez G; Flores C
    Clin Nucl Med; 1999 Feb; 24(2):109-10. PubMed ID: 9988068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cushing's syndrome secondary to bronchial carcinoid tumor: contribution of gammagraphy with 111In-DTPA octreotide in the localization diagnosis].
    Peña González E; Lampreave Márquez JL; León Atance P; Moreno Esteban B; Bittini Copano A; Folqué Gómez E
    An Med Interna; 1999 Nov; 16(11):577-9. PubMed ID: 10637999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Octreotide-sensitive ectopic ACTH production by islet cell carcinoma with multiple liver metastases.
    Doi M; Imai T; Shichiri M; Tateno T; Fukai N; Ozawa N; Sato R; Teramoto K; Hirata Y
    Endocr J; 2003 Apr; 50(2):135-43. PubMed ID: 12803233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The incidental discovery of follicular thyroid cancer with in-111 pentetreotide scintigraphy in a patient with carcinoid tumor of the lung.
    Villa G; Ratto GB; Carletto M; Rouhanifar H; Piccardo A; Tommasi L; Altrinetti V; Mereu C; Mariani G
    Clin Nucl Med; 2003 Jan; 28(1):45-6. PubMed ID: 12493962
    [No Abstract]   [Full Text] [Related]  

  • 40. In-111 octreotide scan in a case of a neuroendocrine tumor of unknown origin.
    Fuster D; Navasa M; Pons F; Vidal-Sicart S; Mateos JJ; Lomeña F; Rodes J; Herranz R
    Clin Nucl Med; 1999 Dec; 24(12):955-8. PubMed ID: 10595476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.